CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG0724 (clinicaltrials.gov NCT No: NCT00980954)
Title:PHASE III RANDOMIZED STUDY OF CONCURRENT CHEMOTHERAPY AND PELVIC RADIATION THERAPY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY IN HIGH-RISK PATIENTS WITH EARLY-STAGE CERVICAL CARCINOMA FOLLOWING RADICAL HYSTERECTOMY
Principal Investigator:Ann Klopp
Treatment Agent:Carboplatin; Cisplatin; Paclitaxel; Radiation
Study Status:Open
Study Description:The purpose of this study is to compare the effects, good and/or bad, of giving
additional chemotherapy to you after the usual treatment of chemotherapy and
radiation for your cervical cancer. The standard treatment for your type of
cervical cancer is cisplatin chemotherapy plus radiation. The study will
determine whether adding chemotherapy with carboplatin and paclitaxel
(experimental for your type of cervical cancer) to standard radiation and
cisplatin chemotherapy improves survival without increasing side effects.

Hide details for General InformationGeneral Information

Disease Group:Cervix
Phase of Study:Phase III
Treatment Agents:Carboplatin
Cisplatin
Paclitaxel
Radiation
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NRG Oncology (NRG)
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ann Klopp
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-6830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults